Imitrex is a drug owned by Glaxosmithkline. It is protected by 4 US drug patents filed in 2013 out of which all have expired. Based on its patents and exclusivities, its generic launch date is estimated to be Mar 10, 2014. Details of Imitrex's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
|
US5554639 (Pediatric) | Medicaments |
Mar, 2014
(10 years ago) |
Expired
|
| US5554639 | Medicaments |
Sep, 2013
(11 years ago) |
Expired
|
|
US5307953 (Pediatric) | Single dose dispenser having a piercing member |
Jun, 2013
(11 years ago) |
Expired
|
| US5307953 | Single dose dispenser having a piercing member |
Dec, 2012
(11 years ago) |
Expired
|
US patents provide insights into the exclusivity only within the United States, but Imitrex is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Imitrex's family patents as well as insights into ongoing legal events on those patents.
Imitrex's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Imitrex's generic launch date based on the expiry of its last outstanding patent is estimated to be Mar 10, 2014 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Imitrex Generic API suppliers:
Sumatriptan is the generic name for the brand Imitrex. 5 different companies have already filed for the generic of Imitrex, with Lannett Co Inc having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Imitrex's generic
Alternative Brands for Imitrex
Imitrex which is used for treating migraine., has several other brand drugs using the same active ingredient (Sumatriptan). Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
| Drug Owner | Drug Name | ||
|---|---|---|---|
| Currax |
| ||
| Endo Operations |
| ||
| Meridian Medcl |
| ||
| Teva Branded Pharm |
| ||
| Tonix Meds |
|
Apart from brand drugs containing the same ingredient, some generics have also been filed for Sumatriptan, Imitrex's active ingredient. Check the complete list of approved generic manufacturers for Imitrex
About Imitrex
Imitrex is a drug owned by Glaxosmithkline. It is used for treating migraine. Imitrex uses Sumatriptan as an active ingredient. Imitrex was launched by Glaxosmithkline in 1997.
Approval Date:
Imitrex was approved by FDA for market use on 26 August, 1997.
Active Ingredient:
Imitrex uses Sumatriptan as the active ingredient. Check out other Drugs and Companies using Sumatriptan ingredient
Treatment:
Imitrex is used for treating migraine.
Dosage:
Imitrex is available in spray form for nasal use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 20MG/SPRAY | SPRAY | Prescription | NASAL |
| 5MG/SPRAY | SPRAY | Prescription | NASAL |
| 10MG/SPRAY | SPRAY | Discontinued | NASAL |